Veeva Systems Inc. (NYSE:VEEV) Holdings Raised by Blair William & Co. IL

Blair William & Co. IL boosted its stake in Veeva Systems Inc. (NYSE:VEEV) by 0.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,216,231 shares of the technology company’s stock after acquiring an additional 3,608 shares during the quarter. Veeva Systems comprises 0.7% of Blair William & Co. IL’s holdings, making the stock its 27th biggest position. Blair William & Co. IL’s holdings in Veeva Systems were worth $255,713,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Sava Infond d.o.o. acquired a new position in shares of Veeva Systems during the fourth quarter valued at approximately $1,074,000. JPMorgan Chase & Co. boosted its stake in Veeva Systems by 17.5% during the 4th quarter. JPMorgan Chase & Co. now owns 3,005,633 shares of the technology company’s stock valued at $631,935,000 after purchasing an additional 447,041 shares in the last quarter. Elo Mutual Pension Insurance Co increased its position in shares of Veeva Systems by 13.6% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 15,397 shares of the technology company’s stock valued at $3,237,000 after purchasing an additional 1,840 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Veeva Systems by 11.3% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 113,132 shares of the technology company’s stock worth $24,101,000 after buying an additional 11,465 shares in the last quarter. Finally, Korea Investment CORP lifted its holdings in shares of Veeva Systems by 9.1% in the fourth quarter. Korea Investment CORP now owns 186,768 shares of the technology company’s stock valued at $39,268,000 after buying an additional 15,579 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems Price Performance

VEEV opened at $235.52 on Thursday. The company has a market capitalization of $38.24 billion, a PE ratio of 58.15, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. The business has a 50-day moving average of $230.82 and a 200-day moving average of $222.68. Veeva Systems Inc. has a fifty-two week low of $170.25 and a fifty-two week high of $258.93.

Analysts Set New Price Targets

Several equities research analysts have commented on VEEV shares. Truist Financial boosted their price target on shares of Veeva Systems from $210.00 to $217.00 and gave the stock a “hold” rating in a research report on Thursday, March 6th. StockNews.com upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating in a report on Monday, February 17th. Citigroup raised their target price on shares of Veeva Systems from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Barclays upped their price target on Veeva Systems from $260.00 to $275.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Finally, Piper Sandler raised their price objective on Veeva Systems from $280.00 to $290.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Veeva Systems has an average rating of “Moderate Buy” and a consensus price target of $256.52.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.